Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Subbiah

Showing results (51-60 of 60) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 60 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 21, 2016
Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocolF Meric-Bernstam, L Brusco, M Daniels, et al.
ESMO Open|March 15, 2021
Safety and activity of vandetanib in combination with everolimus in patients with advanced solid tumors: a phase I studyT Cascone, R L Sacks, I M Subbiah, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 26, 2024
The ESMO Tumour-Agnostic Classifier and Screener (ETAC-S): a tool for assessing tumour-agnostic potential of molecularly guided therapies and for steering drug developmentC B Westphalen, D Martins-Branco, J R Beal, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 24, 2023
HER2-low expression in patients with advanced or metastatic solid tumorsB Uzunparmak, C Haymaker, G Raso, et al.
ESMO Open|September 3, 2021
PIK3CA mutations in plasma circulating tumor DNA predict survival and treatment outcomes in patients with advanced cancersE E Dumbrava, S G Call, H J Huang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 19, 2018
Selective RET kinase inhibition for patients with RET-altered cancersV Subbiah, V Velcheti, B B Tuch, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 21, 2016
Multiplex KRASG12/G13 mutation testing of unamplified cell-free DNA from the plasma of patients with advanced cancers using droplet digital polymerase chain reactionF Janku, H J Huang, T Fujii, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 7, 2025
ESMO Precision Oncology Working Group recommendations on the structure and quality indicators for molecular tumour boards in clinical practiceC B Westphalen, L Boscolo Bielo, P Aftimos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 16, 2022
Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trialF Griesinger, G Curigliano, M Thomas, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 11, 2018
Targeted methylation sequencing of plasma cell-free DNA for cancer detection and classificationL Liu, J M Toung, A F Jassowicz, et al.
Pageof 6

Showing results (51-60 of 60) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 60 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 21, 2016
Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocolF Meric-Bernstam, L Brusco, M Daniels, et al.
ESMO Open|March 15, 2021
Safety and activity of vandetanib in combination with everolimus in patients with advanced solid tumors: a phase I studyT Cascone, R L Sacks, I M Subbiah, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 26, 2024
The ESMO Tumour-Agnostic Classifier and Screener (ETAC-S): a tool for assessing tumour-agnostic potential of molecularly guided therapies and for steering drug developmentC B Westphalen, D Martins-Branco, J R Beal, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 24, 2023
HER2-low expression in patients with advanced or metastatic solid tumorsB Uzunparmak, C Haymaker, G Raso, et al.
ESMO Open|September 3, 2021
PIK3CA mutations in plasma circulating tumor DNA predict survival and treatment outcomes in patients with advanced cancersE E Dumbrava, S G Call, H J Huang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 19, 2018
Selective RET kinase inhibition for patients with RET-altered cancersV Subbiah, V Velcheti, B B Tuch, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 21, 2016
Multiplex KRASG12/G13 mutation testing of unamplified cell-free DNA from the plasma of patients with advanced cancers using droplet digital polymerase chain reactionF Janku, H J Huang, T Fujii, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 7, 2025
ESMO Precision Oncology Working Group recommendations on the structure and quality indicators for molecular tumour boards in clinical practiceC B Westphalen, L Boscolo Bielo, P Aftimos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 16, 2022
Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trialF Griesinger, G Curigliano, M Thomas, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 11, 2018
Targeted methylation sequencing of plasma cell-free DNA for cancer detection and classificationL Liu, J M Toung, A F Jassowicz, et al.
Pageof 6